Ponatinib Hydrochloride

Ponatinib Hydrochloride · BCR-ABL1 Tyrosine Kinase Inhibitor

Back to Cancer Drug Encyclopedia Find Recruiting Trials with this Drug →

Indications & Uses

Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML) and Ph+ Acute Lymphoblastic Leukemia (ALL).

Contraindications

Hypersensitivity to active ingredient or any formulation excipients.

Side Effects & Warnings

Fluid retention/edema, cytopenias, vascular occlusion (ponatinib), QTc prolongation, pancreatitis, pleural effusion.

Drug & Dietary Interactions

Caution with strong CYP3A inhibitors or inducers; review concurrent medications.

For educational and informational purposes only. Do not alter medication doses or regimens without consulting your licensed oncology physician or care team.

Patient & Caregiver Support

Ask About This Medication

Connect with an ONC-ORG counselor regarding drug access, copay relief, patient assistance programs, or related clinical trials.